Cell Rep:科学家找到治疗滤泡性淋巴瘤的关键

2019-02-23 顾然 生物探索

“T细胞在人体对抗滤泡性淋巴瘤(follicular lymphoma)的过程中起着至关重要的作用。”这是梅奥诊所(Mayo Clinic)血液学家Zhi Zhang Yang和Stephen Ansell领导的一项研究得出的结论。研究结果发表在《Cell Reports》杂志上。T细胞是免疫系统的关键部分,通过对抗感染和癌症来保护身体。“滤泡淋巴瘤是一种主要累及体内淋巴结的血癌,”Yang说,虽

“T细胞在人体对抗滤泡性淋巴瘤(follicular lymphoma)的过程中起着至关重要的作用。”这是梅奥诊所(Mayo Clinic)血液学家Zhi Zhang Yang和Stephen Ansell领导的一项研究得出的结论。研究结果发表在《Cell Reports》杂志上。

T细胞是免疫系统的关键部分,通过对抗感染和癌症来保护身体。

“滤泡淋巴瘤是一种主要累及体内淋巴结的血癌,”Yang说,虽然这种疾病很常见,而且预后比其他癌症要好,但它是无法治愈的。即便许多病人对治疗有反应,但癌症在治疗后复发是很常见的。

Yang博士和他的同事们很好奇为什么有些滤泡淋巴瘤患者的病情比其他患者要好。他们的研究发现,对这种疾病免疫应答较差的患者T细胞上的共刺激受体较少。

“细胞表面存在共刺激受体,使免疫系统能够更好地识别和攻击癌细胞,”Yang博士说。“我们还发现,在滤泡淋巴瘤患者中,T细胞缺乏共刺激受体的患者比T细胞表现出共刺激受体的患者生存时间明显短。”

Yang医生说,虽然这项研究还处于临床前和初步阶段,但最终可能会有临床意义。“如果我们能实施一项策略,在这种T细胞亚群的患者中恢复共刺激受体的表达,我们可能会开发出一种新的治疗滤泡淋巴瘤的方法。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871166, encodeId=ef2018e1166f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 06 23:27:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961444, encodeId=e1421961444f6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 02 03:27:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362215, encodeId=74be36221561, content=努力学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Mar 07 21:26:51 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278793, encodeId=c4bb12e879322, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Feb 25 03:27:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871166, encodeId=ef2018e1166f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 06 23:27:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961444, encodeId=e1421961444f6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 02 03:27:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362215, encodeId=74be36221561, content=努力学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Mar 07 21:26:51 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278793, encodeId=c4bb12e879322, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Feb 25 03:27:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2019-07-02 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871166, encodeId=ef2018e1166f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 06 23:27:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961444, encodeId=e1421961444f6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 02 03:27:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362215, encodeId=74be36221561, content=努力学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Mar 07 21:26:51 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278793, encodeId=c4bb12e879322, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Feb 25 03:27:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2019-03-07 zwjnj2

    努力学习天天学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1871166, encodeId=ef2018e1166f9, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Sep 06 23:27:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961444, encodeId=e1421961444f6, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Jul 02 03:27:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362215, encodeId=74be36221561, content=努力学习天天学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM6DGOvNrRdcib3UmzMgpEQpl0ENSJScphsFtdgfibXX1g1IuEYGCjP23UqCd52TxTpSZibtPiclyusaHicnNXd78alaia19Qy1nAFo18/0, createdBy=50381491660, createdName=zwjnj2, createdTime=Thu Mar 07 21:26:51 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278793, encodeId=c4bb12e879322, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66587, encryptionId=5bd36658e94, topicName=滤泡性淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a5a149, createdName=gongliu, createdTime=Mon Feb 25 03:27:00 CST 2019, time=2019-02-25, status=1, ipAttribution=)]

相关资讯

PNAS:免疫力差?T细胞“灰化”是根源!

相对于一般人群,老年人感染后会有更严重的并发症,接种疫苗也受益更少,众所周知,免疫系统弱是罪魁祸首,但是这种滞后免疫背后的确切机制在很大程度上仍不清楚。 现在由哈佛医学院的研究人员领导的研究表明,免疫T细胞的新陈代谢减弱可能是部分原因。

肿瘤个性化治疗——肿瘤新抗原Neoantigen疗法首次获批进入临床试验

Achilles Therapeutics现已成为临床阶段的生物技术公司,获得监管部门的批准,开始其肺癌治疗的1/2期临床试验。该公司正在开发针对肿瘤"新抗原"的个性化T细胞疗法。

Sci Transl Med:盐竟然是过敏免疫反应的罪魁祸首之一?

相信很多人都遭受过敏的影响,特别是一些儿童会患有特应性皮炎,让宝妈们烦恼不已。通常在这种免疫条件下,“人体健康卫士”T细胞就会发挥重要的作用,它可以帮助我们抵抗感染。但是这种反应如果不加以控制,也会产生病理反应,进而攻击我们身体的某些部位或过敏原等无害物质。这当中,T细胞的一个亚群——Th2细胞可以引起炎症性皮肤状况,如特应性皮炎。这涉及到白细胞介素4(IL-4)和白细胞介素13(IL-13)蛋白

Cell Stem Cell: 再生抗癌T细胞问世!绝杀肿瘤细胞!

去年,“免疫细胞刹车”新概念问世,利用免疫系统的能力来攻击癌症细胞,在癌症免疫疗法的发展中做出了开拓性贡献。一石激起千层浪,免疫细胞疗法再次掀起了热议,而该疗法发挥作用的关键便是T细胞,去年一年关于它的研究也是从未间断。

JAHA:调节性T细胞可以保护高血压引起的脑血管损伤

免疫细胞是高血压血管炎症反应的关键调控因子,在高血压啮齿动物中,有调控作用的T淋巴细胞(调节性T细胞、CD4+CD25+)可以保护血管的损伤、心脏的损伤和肠系膜动脉的内皮功能。然而,调节性T细胞能否保护高血压引起的脑血管损伤尚不清楚。本研究对C57BL/6小鼠进行了血管紧张素II(AngII; 1000ng/kg 每分钟)灌注处理14天,并通过2次静脉内注射灌输了3×105个CD4+CD25+T细

Nature:中科院科学家首次揭开PD-1蛋白降解机制,白介素-2可促进该过程,增强T细胞抗癌能力

提起肿瘤免疫治疗,离不开PD-1。咱们知道这个蛋白给免疫系统踩了刹车,让癌细胞有机可乘,那么除了直接用单抗拮抗,还有没有其他的办法能干掉它呢?